1 In this study,
we aimed to assess 8-week treatment with ombitasvir, paritapr
2 We aimed to assess changes in molecular signatures of intrapa
3 We aimed to assess colposcopy referral and CIN2+ detection ra
4 We aimed to assess CPC's effects on mitochondrial toxicity an
5 In this study (ASPIRE),
we aimed to assess eltrombopag, an oral thrombopoietin recept
6 We aimed to assess glycaemic outcomes when switching from mul
7 We aimed to assess molecular differences in the nucleus accum
8 We aimed to assess mortality by occupation in the UK, differe
9 We aimed to assess the activity and safety of dabrafenib plus
10 We aimed to assess the benefit of MDT in a randomized phase I
11 We aimed to assess the benefits of LDL-C lowering on cardiova
12 We aimed to assess the effect of an intensified dosing schedu
13 We aimed to assess the effect of demographic, clinical, and h
14 We aimed to assess the effect of implementing a comprehensive
15 We aimed to assess the effects of an eight-session support gr
16 We aimed to assess the efficacy and safety of ceftazidime-avi
17 We aimed to assess the efficacy and safety of idelalisib in c
18 We aimed to assess the efficacy and safety of long-acting pas
19 We aimed to assess the efficacy and safety of pacritinib vers
20 We aimed to assess the efficacy and safety of regorafenib in
21 We aimed to assess the efficacy and safety of sirukumab for r
22 We aimed to assess the electrophysiological properties of CI
23 We aimed to assess the impact of a 70-gene signature (70-GS)
24 We aimed to assess the in vivo function of CYP2A13 and CYP2F1
25 We aimed to assess the link between climatic factors and occu
26 We aimed to assess the long-term safety and efficacy of the p
27 We aimed to assess the persistence of bactericidal antibodies
28 Herein,
we aimed to assess the potential role of protein-modifying va
29 We aimed to assess the presence of CMV DNA in the blood of ad
30 We aimed to assess the prognostic and predictive value of a 3
31 evalence and predictors of inflammation in diverse settings.
We aimed to assess the relation between inflammation (CRP con
32 We aimed to assess the relationship between the myocardial lo
33 left ventricular ejection fraction have Vmax in this range,
we aimed to assess the relationship between Vmax and mortalit
34 We aimed to assess the risk of developing diabetes mellitus a
35 We aimed to assess the risk of Sabin 2 transmission after a p
36 In this phase 2 study,
we aimed to assess the safety and activity of two doses and s
37 Therefore,
we aimed to assess the safety and efficacy of ozanezumab in p
38 We aimed to assess the safety, tolerability, pharmacokinetics
39 We aimed to assess the scale of this problem and whether it i
40 We aimed to assess the use of ATS and the perceived barriers
41 We aimed to assess the validity of the previous symptom-based
42 We aimed to assess what proportion of variants associated wit
43 We aimed to assess whether a patient-specific molecular signa
44 We aimed to assess whether bihormonal bionic pancreas initial
45 We aimed to assess whether custirsen in combination with caba
46 We aimed to assess whether high eosinophil concentrations in
47 We aimed to assess whether implementation of VISHRAM was asso
48 We aimed to assess whether provision of mindfulness courses t
49 We aimed to assess whether short message service (SMS) remind
50 We aimed to assess whether the MC4R genotype affected longitu